Raw materials such as dogwood are rising, and the cost of Yibai Pharmaceutical is increasing!

On August 25, 2022, Guizhou Yibai Pharmaceutical Co.
, Ltd.
(Yibai Pharmaceutical, 600594) released its 2022 interim report showing that in the first half of 2022, Yibai Pharmaceutical achieved revenue of 1.
446 billion yuan, down 14.
28% year-on-year; Net profit was 126 million yuan, down 23.
12%
year-on-year.
Figure 1: 2016-2021 Yibai Pharmaceutical core business data First, traditional Chinese medicine anti-tumor is mainly injectable According to the data of the hospital terminal and retail terminal of the Minet, among the traditional Chinese medicines used for tumor diseases, the sales of drugs for oncology diseases are the highest
.
In 2020, the sales volume of traditional Chinese medicines for oncology diseases reached 16.
350 billion yuan, of which the amount of drugs for oncology diseases in hospitals was 15.
304 billion yuan, accounting for 93.
61%.

From the perspective of dosage forms, the dosage forms used for tumor diseases mainly include injections, powders, granules, tablets, pills and solutions, etc.
, of which the sales of injections reached 9.
256 billion yuan, accounting for 56.
61%.

Yibai Pharmaceutical's anti-tumor proprietary Chinese medicines account for a relatively large proportion of Yibai Pharmaceutical's drugs cover a number of pharmaceutical subdivisions such as chemical drugs, proprietary Chinese medicines and biological drugs, involving oncology, cardiovascular and cerebrovascular diseases, gynecology, pediatrics, orthopedics and respiration and other treatment areas
。 Among them, the main products of proprietary Chinese medicine include anti-tumor (Aidi injection, compound cantharist capsules, Aiyu capsules), cardiovascular and cerebrovascular classes (heart pulse capsules, Liqi active blood drop pills, Dandeng Tong brain drop pills), gynecology (gynecological anti-inflammatory capsules, Baogong hemostatic granules, gynecological adjustment prayer drops and rock deer milk Kang tablets), pediatric (Golden Lotus Qing heat effervescent tablets), others (Golden Lotus capsules, heart-stomach pain relief capsules and cough family products).

In this issue, the big data platform of traditional Chinese medicine industry in Tiandi Cloud Map analyzes the cost pressure of traditional Chinese medicine raw materials faced by enterprises from the perspective of
raw materials involved in compound cantharids capsules.
Table 1: Compound cantharids capsules core raw materials Compound cantharids capsules can break blood and eliminate stasis, attack poison erosion sores, and is used for the treatment
of primary liver cancer, lung cancer, rectal cancer, malignant lymphoma, gynecological malignant tumors, etc.
Fourth, the compound cantharids capsule raw materials rise and fall Table 2: compound canker capsule raw materials rise and fall During the period from January 2021 to September 2022, the prices of 7 kinds of raw materials rose, accounting for 64%, the prices of 2 raw materials were flat, accounting for 13%, and the prices of 2 raw materials fell, accounting for 13%.

Fifth, compound canker capsule raw material market analysis Cantharid, the price of cantharids in the first two years is high, resulting in increased farmers' enthusiasm for harvesting, and the yield has increased
.
Most of this variety is operated by franchisees, and few merchants have paid attention to it this year, and the supply has been slow
.
Affected by this, the market fell into a downturn, the current market for small goods more than the asking price of about 850 yuan (kilogram price, the same below), large goods price of about
1100 yuan.
Ginseng, the new production continues, this year's production area rains more, but the market supply of goods, the recent merchants small batch procurement, the source of goods moving around, the market is running stably, the price of 80 raw drying goods is between 255-260 yuan, and the price of raw sunning 45 is between
320-330 yuan.
Astragalus, affected by the drought in Gansu, some time ago the price of astragalus rose, recently moved smoothly, the market has not fluctuated significantly, the current market in the market more than 20 yuan asking price, small strip price at 16-17 yuan
.
Merchants pay attention to the new production
.
Eleuthero plus, near the futures source in the normal purchase and sale state, the merchant attention is general, the market has been in a stable state, the current market price of eleuthero bar piece is 14 yuan, eleuthero root piece sieve price between 20-22 yuan
.
This year's production area is not large, and the future market pays attention to the actual digestion of the source of goods
.
Three edges, the market supply is sufficient, sometimes there are places of origin to supplement the goods, the source of goods is slow to sell, the market is weaker than the previous performance, the current market price of Zhejiang goods is between 22-23 yuan, Jiangxi goods are priced between
16-17 yuan.
The future market pays attention to the digestion of the source of goods
.
Half a lotus, new goods continue to fill the market, the market supply to normal digestion and movement, the market is slippery, the price of the current cut section of the unified goods between
12-12.
5 yuan.
Although the previous production area was affected by drought, the actual output this year was acceptable, and the market was flat.

Curcumin, the market supply is sufficient, there is a recent demand for manufacturers to buy, the supply and demand of the supply is flat, the market has performed flat in recent times, the price of small and medium-sized films in Guangxi is between 16-17 yuan, the price of large films is 18-19 yuan, and the price of Yunnan unified films is 17-18 yuan
.
Dogwood, merchants normal purchase and sale, the market supply of goods, the recent market to maintain a smooth operation, the spot price of goods between 47-48 yuan, the price of good goods in 52-55 yuan
.
Some areas of the production area have encountered hail weather, and the future focus is on new production
.
Sixth, comprehensive review 1, dogwood and other varieties of procurement cost pressure is relatively large raw material stress test shows that the current compound cantharids capsule raw materials from the supply pressure, mainly from the dogwood, half lotus, curcumin, three edges, etc.
; From the perspective of quality pressure, it mainly comes from cankerworms, bear bile powder, etc
.
2, dogwood production is expected to reduce the production of merchants in the production area have reported that this year's dogwood fruit is not as good as in previous years, and some production areas have drought and hail weather, and it is expected that the output in 2022 is not large
.
But on the other hand, the cold storage inventory of dogwood is not small, enough for a year to use, just to see what price these stocks will be shipped
.
Only from the supply and demand situation in 2021, the stock is greater than the demand, and there is no basis for a substantial increase in the price of
dogwood.
In summary, Yibai Pharmaceutical's business is affected by the policies of the pharmaceutical industry, the price of injection dosages of proprietary Chinese medicines has dropped twice, the overall sales situation is under pressure, and the cost of raw materials has increased significantly in the past two years, and the company's procurement pressure is not small
.
However, as the market for multiple core raw materials stabilizes or declines, the upward pressure on raw material costs will gradually ease
.
First, traditional Chinese medicine anti-tumor injection-based hospitals two, Yibai pharmaceutical industry anti-tumor proprietary Chinese medicine accounted for a relatively large proportion of pharmaceutical enterprises three, compound cantharids capsule core raw materials four, compound cantharids capsule raw materials rise and fall fifth, compound cantharids capsule raw materials market analysis and procurement six, comprehensive reviews